Table 1.
Clinicopathologic and molecular characteristics of 1,834 endometrial cancers according to molecular subtype defined by integrating clinical tumor-normal sequencing and immunohistochemistry data.
| Total n=1,834 | POLE n=97 | MSI-H n=428 | CN-H n=734 | CN-L n=575 | p value* | |
|---|---|---|---|---|---|---|
| Age at diagnosis years, median (range) | ||||||
| BMI kg/m2, median (range) | 29.6 (14.9–67.6) | 26.3 (17.7–43.0) | 30.5 (16.6–59.3) | 29.1 (17.5–66.2) | 30.7 (14.9–67.6) | <0.001 |
| Histology, n (%) | <0.001 | |||||
| Endometrioid | 976 (53) | 75 (77) | 345 (81) | 74 (10) | 482 (84) | |
| Serous | 274 (15) | 0 | 3 (0.7) | 265 (36) | 6 (1) | |
| Clear Cell | 56 (3.1) | 1 (1) | 4 (0.9) | 31 (4.2) | 20 (3.5) | |
| Carcinosarcoma | 223 (12) | 0 | 14 (3.3) | 195 (27) | 14 (2.4) | |
| De-/ Undifferentiated | 39 (2.1) | 2 (2.1) | 25 (5.8) | 4 (0.5) | 8 (1.4) | |
| Mixed/ high-grade NOS | 170 (9.3) | 10 (10) | 28 (6.5) | 115 (16) | 17 (3) | |
| Other | 96 (5.2) | 9 (9.3) | 9 (2.1) | 50 (6.8) | 28 (4.9) | |
| Endometrioid grade, n (%) | <0.001 | |||||
| 1 | 473 (50) | 25 (35) | 128 (38) | 19 (28) | 301 (64) | |
| 2 | 287 (30) | 22 (31) | 131 (39) | 11 (16) | 123 (26) | |
| 3 | 183 (19) | 25 (35) | 74 (22) | 37 (55) | 47 (10) | |
| Stage, n (%) | <0.001 | |||||
| I | 956 (58) | 79 (85) | 256 (66) | 256 (39) | 365 (71) | |
| II | 72 (4.3) | 3 (3.2) | 18 (4.6) | 29 (4.4) | 22 (4.3) | |
| III | 341 (21) | 7 (7.5) | 82 (21) | 182 (28) | 70 (14) | |
| IV | 288 (17) | 4 (4.3) | 34 (8.7) | 190 (29) | 60 (12) | |
| Adjuvant treatment†, n (%) | <0.001 | |||||
| None | 371 (36) | 30 (36) | 95 (35) | 43 (14) | 203 (58) | |
| Chemo +/− RT | 452 (44) | 19 (23) | 108 (40) | 245 (77) | 80 (23) | |
| RT | 199 (19) | 35 (42) | 67 (25) | 30 (9.4) | 67 (19) | |
| Tissue type sequenced, n (%) | <0.001 | |||||
| Primary | 1501 (82) | 93 (97) | 355 (83) | 590 (81) | 463 (81) | |
| Recurrence/ metastasis | 323 (18) | 3 (3) | 73 (17) | 139 (19) | 108 (19) | |
| Tumor purity (%), median (range) | 40 (20–90) | 40 (20–85) | 40 (20–90) | 50 (20–90) | 40 (20–90) | <0.001 |
| TMB (mutations/Mb), median (range) | 6.1 (0.0–667.9) | 159.4 (19.3–667.9) | 30.1 (0.0–397.9) | 4.4 (0.8–74.6) | 6.1 (0.0–228.2) | <0.001 |
| Somatic mutations (n), median (range) | 7 (1–758) | 171 (22–758) | 34 (1–483) | 5 (1–85) | 7 (1–258) | <0.001 |
| Fraction genome altered (%), median (range) | 5.6 (0.0–95.7) | 0.1 (0.0–16.8) | 2.2 (0.0–62.2) | 24.7 (0.0–95.7) | 3.5 (0.0–79.7) | <0.001 |
| MSIsensor score, median (range) | 0.5 (0.0–47.2) | 0.2 (0.0–22.5) | 16.6 (0.0–47.2) | 0.6 (0.0–8.0) | 0.1 (0.0–8.5) | <0.001 |
*
Kruskal-Wallis rank sum test; Fisher’s exact test; Fisher’s Exact Test for Count Data with simulated p-value (based on 2000 replicates)
†
Adjuvant treatment: none, chemotherapy with or without radiation therapy, radiation therapy alone
BMI, body mass index; Chemo, chemotherapy; CN-H, copy number-high; CN-L, copy number-low; MSI-H, microsatellite instability-high; RT, radiotherapy; TMB, tumor mutational burden.